HUTCHMED (China) (HMDCF) Shares Outstanding (2014 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Shares Outstanding (Entity) came in at $174.5 million in Q4 2025, little changed year-over-year from $174.3 million in Q4 2024, and little changed quarter-over-quarter from $174.3 million in Q4 2024.
Analysis
HUTCHMED (China) (HMDCF) Shares Outstanding (2014 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Shares Outstanding (Entity) for 12 consecutive years, with $174.5 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Shares Outstanding (Entity) changed 0.08% year-over-year to $174.5 million in Q4 2025; TTM through Dec 2025 was $174.5 million, a 0.08% change from a year earlier, with the FY2025 full-year figure at $174.5 million, changed 0.08% from the prior year.
- Shares Outstanding (Entity) was $174.5 million for Q4 2025 at HUTCHMED (China), roughly flat from $174.3 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $174.5 million in Q4 2025 and troughed at $172.9 million in Q4 2021.
- A 5-year average of $173.8 million and a median of $174.3 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Across the five-year window, Shares Outstanding (Entity) grew 18.8% in 2021 and climbed 0.03% in 2022, its largest moves.
- Over 5 years, Shares Outstanding (Entity) stood at $172.9 million in 2021, then grew by 0.03% to $173.0 million in 2022, then rose by 0.75% to $174.3 million in 2023, then rose by 0.04% to $174.3 million in 2024, then gained by 0.08% to $174.5 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $174.5 million (Q4 2025), $174.3 million (Q4 2024), and $174.3 million (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | 720.78 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 171.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 171.66 Mn |
| Dec 31, 2025 | 171.66 Mn |
| Jun 30, 2025 | 171.07 Mn |
| Dec 31, 2024 | 171.07 Mn |
| Jun 30, 2024 | 169.93 Mn |
| Dec 31, 2023 | 169.93 Mn |
| Jun 30, 2023 | 169.43 Mn |
| Dec 31, 2022 | 169.43 Mn |
| Jun 30, 2022 | 158.54 Mn |
| Dec 31, 2021 | 158.54 Mn |
| Sep 28, 2021 | 139.59 Mn |
| Jun 30, 2021 | 139.59 Mn |
| Mar 31, 2021 | 139.59 Mn |
| Dec 31, 2020 | 139.59 Mn |
| Jun 30, 2020 | 133.14 Mn |
| Mar 31, 2020 | 133.14 Mn |
| Dec 31, 2019 | 133.14 Mn |
| Sep 30, 2019 | 132.85 Mn |
| Jun 30, 2019 | 132.85 Mn |
| Mar 31, 2019 | 132.85 Mn |